LEAP-012
Regimen
- Experimental
- TACE + lenvatinib + pembrolizumab
- Control
- TACE + dual placebo
Population
Unresectable, non-metastatic hepatocellular carcinoma
Key finding
mPFS 14.6 vs 10.0 mo (HR 0.66, P=0.0002); 24-mo OS 75% vs 69% (HR 0.80, NS at first interim). First positive global phase 3 of TACE + IO + TKI in intermediate-stage HCC. Asian population 72%.
Source: PMID 39798578